You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基蛋生物(603387.SH)擬收購景川診斷54.9624%股份並認購其新增股份
格隆匯 03-18 18:33

格隆匯3月18日丨基蛋生物(603387.SH)公佈,公司擬通過特定事項協議轉讓方式現金收購武漢景川診斷技術股份有限公司(以下簡稱“景川診斷”或“標的公司”)54.9624%的股份,收購總價款為6391.03萬元人民幣;股份轉讓完成後,公司擬按照3.42元/股的價格認購景川診斷新增股份,認購金額為1000.008萬元。本次交易完成後,基蛋生物將持有景川診斷58.5289%的股份,為其第一大股東,景川診斷將成為公司的控股子公司。

景川診斷2006年成立以來,在凝血診斷試劑的研發、生產方面積累了具有自主品牌和自主知識產權的技術和產品。其自主研發的產品主要有BCA系列全自動血凝儀、XN06系列、GDC系列、BCS系列血凝儀、全自動C反應蛋白測定儀、TD系列特定蛋白儀和凝血檢測試劑盒、特定蛋白檢測試劑盒等50多項產品,其中已有43項產品取得了《醫療器械註冊證》並上市銷售,部分產品達到國內領先水平。獲得軟件著作權證書26項,發明專利4項,實用新型專利2項,外觀專利2項。

公司通過本次收購及增資,充分利用公司在體外診斷領域積累的資源,通過景川診斷進入凝血檢測的行業細分領域,更合理地配置資源,開拓公司凝血檢測業務板塊,凝血檢驗在心血管疾病、腦血管疾病診斷中具有重要醫學意義,因此與公司現有心血管檢測業務具有較強協同性,有助公司尋找新的盈利增長點,提升公司的持續盈利能力和長期發展潛力,提升公司價值從而提升股東回報。

截至本公告披露日,景川診斷對外擔保金額為300萬元,均為其控股子公司向銀行貸款擔保。委託理財總額度不超過500萬元,尚在存續期內的理財產品本金餘額合計為235萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account